AVITA Medical Appoints Cary Vance as Permanent CEO and Announces Leadership Changes

Key Highlights for Investors

• Cary Vance appointed as President and Chief Executive Officer (CEO) of AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), effective immediately, following a successful interim tenure and thorough international search.
• Jan Stern Reed elected as the new Chair of the Board, after serving as Lead Independent Director since October 2025.
• Upcoming Q1 2026 earnings call scheduled for May 14, 2026 (U.S.) / May 15, 2026 (Australia).
• Company reiterates its focus on scaling adoption of its RECELL® platform and supporting broader clinician engagement.

Detailed Article

VALENCIA, Calif., April 30, 2026 — AVITA Medical, Inc., a leading company in therapeutic acute wound care, has announced the appointment of Cary Vance as its permanent President and Chief Executive Officer. This decision follows an extensive, top-tier international executive search process, underscoring the Board’s commitment to strong leadership at a pivotal growth stage for the company. Mr. Vance had been serving as Interim CEO since October 2025 and will continue to be an executive member of the Board.

Jan Stern Reed, who has been a board member since 2021 and most recently served as Lead Independent Director, has been elected as the new Chair of the Board. These leadership changes signal a new strategic direction and renewed confidence in AVITA’s growth trajectory.

Leadership Commentary

“Following a thorough search process, the Board unanimously concluded that Cary is the right leader to serve as CEO on a permanent basis,” said Jan Stern Reed. “Over the past six months, Cary has demonstrated decisive leadership at a critical time for the Company, stabilizing the business, sharpening our strategic focus, and rebuilding confidence and enthusiasm with employees, customers, and shareholders. His industry experience and operational discipline position him well as we enter an exciting growth period.”

Cary Vance added, “It has been a privilege to serve as Interim CEO, and I’m honored to continue in this role permanently. Feedback from clinicians at key industry meetings and leading burn and trauma centers has been consistent: our products are driving clinically validated improvements in patient outcomes. We are building real momentum at AVITA. Our focus remains on scaling adoption, supporting more clinicians to deliver better outcomes, and translating that momentum into consistent performance.”

Backgrounds of New Leaders

Cary Vance brings more than 30 years of healthcare executive experience, having previously led companies such as PhotoniCare, Titan Medical, OptiScan Biomedical, MyoScience, Hansen Medical, and XCath. He has also held senior roles at major medical device leaders including Teleflex, Covidien, and GE HealthCare.

Jan Stern Reed is an experienced independent director with over 35 years in healthcare legal and business management, both as an executive and as a board member. Her leadership as the Board’s Lead Independent Director since October 2025 was key in guiding AVITA through recent transitions.

Upcoming Q1 2026 Earnings Call

Investors should note that AVITA Medical will release its first quarter 2026 earnings on May 14, 2026 (U.S. time) / May 15, 2026 (Australian time). The conference call and webcast will offer additional insights into the company’s financial performance and strategic direction. Details are available on the AVITA Medical investor relations website.

Company Overview & Strategic Focus

AVITA Medical’s core technology, RECELL®, is an FDA-approved platform for the treatment of thermal burn and trauma wounds. The device leverages a patient’s own skin to create Spray-On Skin™ for improved healing. In the U.S., AVITA also exclusively markets Cohealyx® (a collagen-based dermal matrix) and PermeaDerm® (a biosynthetic wound matrix). Internationally, RECELL and RECELL GO® are CE-marked in Europe, certified in Australia, and PMDA-approved in Japan.

The company’s strategic focus remains on accelerating the adoption of its acute wound care solutions, expanding its commercial footprint, and maintaining regulatory and operational excellence. These efforts are seen as key drivers for future growth and shareholder value.

Potential Price-Sensitive Developments

• Permanent CEO Appointment: The confirmation of Cary Vance as CEO after a successful interim period can be viewed positively by the market, potentially reducing uncertainty and supporting share value.
• Leadership Stability: The new Chair and experienced management team signal strategic consistency and can boost investor confidence.
• Growth Focus: Renewed emphasis on scaling product adoption and clinical engagement could translate to revenue acceleration and margin improvement.
• Upcoming Earnings: The scheduled Q1 2026 earnings call may provide further updates on commercial progress, adoption rates, and financial metrics, which could impact the stock price.

Forward-Looking Statements

The company cautions that certain statements in this release are forward-looking and subject to significant risks and uncertainties, including market conditions, regulatory factors, supply chain disruptions, and other external economic or political influences. Actual results may differ materially from those expressed or implied.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and review AVITA Medical’s official filings and risk disclosures before making any investment decisions.

View AVITA Medical, Inc. Historical chart here